SillaJen, Inc.
KOSDAQ 215600.KQ
SillaJen, Inc. Revenue for the year ending December 31, 2023: USD 3.03 M
SillaJen, Inc. Revenue is USD 3.03 M for the year ending December 31, 2023, a -23.61% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
-
SillaJen, Inc. Revenue for the year ending December 31, 2022 was USD 3.96 M, a 1,760.28% change year over year.
-
SillaJen, Inc. Revenue for the year ending December 31, 2021 was USD 212.90 K, a -86.11% change year over year.
-
SillaJen, Inc. Revenue for the year ending December 31, 2020 was USD 1.53 M, a -80.39% change year over year.
-
SillaJen, Inc. Revenue for the year ending December 31, 2019 was USD 7.82 M, a 13.38% change year over year.
Key data
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
Market news
Loading...
KOSDAQ: 215600.KQ
| CEO | Mr. Jaekyung Kim |
| IPO Date | Dec. 6, 2016 |
| Location | South Korea |
| Headquarters | O2 Tower |
| Employees | 37 |
| Sector | Health Care |
| Industries | |
Description
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email